RenovoRx, Inc. Files 8-K Report

Ticker: RNXT · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1574094

Renovorx, INC. 8-K Filing Summary
FieldDetail
CompanyRenovorx, INC. (RNXT)
Form Type8-K
Filed DateApr 16, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$2.5 million, $11.1 million
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

RenovoRx filed an 8-K, something happened.

AI Summary

On April 16, 2024, RenovoRx, Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itself, but it indicates a material development for the company. RenovoRx, Inc. is a pharmaceutical preparations company incorporated in Delaware.

Why It Matters

This filing signals a potentially significant event for RenovoRx, Inc. that requires public disclosure, though the specifics are not yet detailed.

Risk Assessment

Risk Level: medium — The filing of an 8-K indicates a material event, but the lack of detail in this specific filing creates uncertainty about the nature and impact of the event.

Key Players & Entities

FAQ

What specific event is reported in this 8-K filing by RenovoRx, Inc.?

The filing is an "Other Event" and does not specify the exact nature of the event.

When was the earliest event reported in this filing?

The earliest event reported was on April 16, 2024.

In which state is RenovoRx, Inc. incorporated?

RenovoRx, Inc. is incorporated in Delaware.

What is the Commission File Number for RenovoRx, Inc.?

The Commission File Number for RenovoRx, Inc. is 001-40738.

What is the address of RenovoRx, Inc.'s principal executive offices?

The address is 4546 El Camino Real, Suite B1 Los Altos, CA 94022.

Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-04-16 08:00:40

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RenovoRx, Inc. Date: April 16, 2024 By: /s/ Shaun Bagai Name: Shaun R. Bagai Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing